SEHK:6990Biotechs
Assessing Kelun-Biotech (SEHK:6990) Valuation After NMPA IND Approval For Long Acting Autoimmune Antibody
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) just cleared a key hurdle in autoimmune drug development, with China’s NMPA approving the IND for SKB575/HBM7575, a long acting bispecific antibody for atopic dermatitis.
See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical.
The IND approval landed as Sichuan Kelun-Biotech Biopharmaceutical’s 1 day share price return of 1.75% and 7 day share price return of 2.23% contrast with a 30 day share price return of about a 10%...